HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Elmar A. Joura; Susanne K. Kjaer; Cosette M. Wheeler; Kristján Sigurdsson; Ole Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R. Brown; Laura A. Koutsky; Eng Hseon Tay; Patricia García; Kevin A. Ault; Suzanne M. Garland; Sepp Leodolter; Sven Eric Olsson; Grace W.K. Tang; Daron G. Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; Xavier Bosch; Joakim Dillner; Robert J. Kurman; Slawomir Majewski; Nubia Muñoz; Evan R. Myers; Luisa L. Villa; Frank J. Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C. Lupinacci; Katherine E.D. Giacoletti; Shuang Lu; Scott Vuocolo; Teresa M. Hesley; Richard M. Haupt; Eliav Barr

doi:10.1016/j.vaccine.2008.09.073

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Elmar A. Joura
, Susanne K. Kjaer
, Cosette M. Wheeler
, Kristján Sigurdsson
, Ole Erik Iversen
, Mauricio Hernandez-Avila
, Gonzalo Perez
, Darron R. Brown
, Laura A. Koutsky
, Eng Hseon Tay
, Patricia García
, Kevin A. Ault
, Suzanne M. Garland
, Sepp Leodolter
, Sven Eric Olsson
, Grace W.K. Tang
, Daron G. Ferris
, Jorma Paavonen
, Matti Lehtinen
, Marc Steben

Xavier Bosch, Joakim Dillner, Robert J. Kurman, Slawomir Majewski, Nubia Muñoz, Evan R. Myers, Luisa L. Villa, Frank J. Taddeo, Christine Roberts, Amha Tadesse, Janine Bryan, Lisa C. Lupinacci, Katherine E.D. Giacoletti, Shuang Lu, Scott Vuocolo, Teresa M. Hesley, Richard M. Haupt, Eliav Barr

School of Public Health and Administration

Medical University of Vienna
Rigshospitalet
University of New Mexico School of Medicine
National Cancer Detection Clinic
University of Bergen
National Institute of Public Health
Universidad del Rosario
Indiana University School of Medicine
School of Public Health
KK Women's And Children's Hospital
Emory University School of Medicine
Royal Women's Hospital, Carlton
Danderyd Hospital
University of Hong Kong
Medical College of Georgia
Helsinki University Hospital
University of Tampere
Institut National de Santé Publique du Québec
IDIBELL
Lund University
Johns Hopkins University School of Medicine
Medical University of Warsaw
National Institute of Cancer
Duke University Medical Center
Ludwig Institute for Cancer Research Sao Paulo
Inc.

Research output: Contribution to journal › Article › peer-review

177 Scopus citations

Abstract

The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.

Original language	English
Pages (from-to)	6844-6851
Number of pages	8
Journal	Vaccine
Volume	26
Issue number	52
DOIs	https://doi.org/10.1016/j.vaccine.2008.09.073
State	Published - 9 Dec 2008

Keywords

Human Papillomavirus
Humoral immunity
Immune memory

Access to Document

10.1016/j.vaccine.2008.09.073

Cite this

Joura, E. A., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., Ault, K. A., Garland, S. M., Leodolter, S., Olsson, S. E., Tang, G. W. K., Ferris, D. G., Paavonen, J., Lehtinen, M., ... Barr, E. (2008). HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine, 26(52), 6844-6851. https://doi.org/10.1016/j.vaccine.2008.09.073

@article{6d0bdc9e5f8c49ac8e5c84fc464e8c49,

title = "HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine",

abstract = "The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40\% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4\%; 95\% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.",

keywords = "Human Papillomavirus, Humoral immunity, Immune memory",

author = "Joura, \{Elmar A.\} and Kjaer, \{Susanne K.\} and Wheeler, \{Cosette M.\} and Kristj{\'a}n Sigurdsson and Iversen, \{Ole Erik\} and Mauricio Hernandez-Avila and Gonzalo Perez and Brown, \{Darron R.\} and Koutsky, \{Laura A.\} and Tay, \{Eng Hseon\} and Patricia Garc{\'i}a and Ault, \{Kevin A.\} and Garland, \{Suzanne M.\} and Sepp Leodolter and Olsson, \{Sven Eric\} and Tang, \{Grace W.K.\} and Ferris, \{Daron G.\} and Jorma Paavonen and Matti Lehtinen and Marc Steben and Xavier Bosch and Joakim Dillner and Kurman, \{Robert J.\} and Slawomir Majewski and Nubia Mu{\~n}oz and Myers, \{Evan R.\} and Villa, \{Luisa L.\} and Taddeo, \{Frank J.\} and Christine Roberts and Amha Tadesse and Janine Bryan and Lupinacci, \{Lisa C.\} and Giacoletti, \{Katherine E.D.\} and Shuang Lu and Scott Vuocolo and Hesley, \{Teresa M.\} and Haupt, \{Richard M.\} and Eliav Barr",

year = "2008",

month = dec,

day = "9",

doi = "10.1016/j.vaccine.2008.09.073",

language = "Ingl{\'e}s",

volume = "26",

pages = "6844--6851",

journal = "Vaccine",

issn = "0264-410X",

number = "52",

}

Joura, EA, Kjaer, SK, Wheeler, CM, Sigurdsson, K, Iversen, OE, Hernandez-Avila, M, Perez, G, Brown, DR, Koutsky, LA, Tay, EH, García, P, Ault, KA, Garland, SM, Leodolter, S, Olsson, SE, Tang, GWK, Ferris, DG, Paavonen, J, Lehtinen, M, Steben, M, Bosch, X, Dillner, J, Kurman, RJ, Majewski, S, Muñoz, N, Myers, ER, Villa, LL, Taddeo, FJ, Roberts, C, Tadesse, A, Bryan, J, Lupinacci, LC, Giacoletti, KED, Lu, S, Vuocolo, S, Hesley, TM, Haupt, RM & Barr, E 2008, 'HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine', Vaccine, vol. 26, no. 52, pp. 6844-6851. https://doi.org/10.1016/j.vaccine.2008.09.073

TY - JOUR

T1 - HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

AU - Joura, Elmar A.

AU - Kjaer, Susanne K.

AU - Wheeler, Cosette M.

AU - Sigurdsson, Kristján

AU - Iversen, Ole Erik

AU - Hernandez-Avila, Mauricio

AU - Perez, Gonzalo

AU - Brown, Darron R.

AU - Koutsky, Laura A.

AU - Tay, Eng Hseon

AU - García, Patricia

AU - Ault, Kevin A.

AU - Garland, Suzanne M.

AU - Leodolter, Sepp

AU - Olsson, Sven Eric

AU - Tang, Grace W.K.

AU - Ferris, Daron G.

AU - Paavonen, Jorma

AU - Lehtinen, Matti

AU - Steben, Marc

AU - Bosch, Xavier

AU - Dillner, Joakim

AU - Kurman, Robert J.

AU - Majewski, Slawomir

AU - Muñoz, Nubia

AU - Myers, Evan R.

AU - Villa, Luisa L.

AU - Taddeo, Frank J.

AU - Roberts, Christine

AU - Tadesse, Amha

AU - Bryan, Janine

AU - Lupinacci, Lisa C.

AU - Giacoletti, Katherine E.D.

AU - Lu, Shuang

AU - Vuocolo, Scott

AU - Hesley, Teresa M.

AU - Haupt, Richard M.

AU - Barr, Eliav

PY - 2008/12/9

Y1 - 2008/12/9

N2 - The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.

AB - The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.

KW - Human Papillomavirus

KW - Humoral immunity

KW - Immune memory

UR - https://www.scopus.com/pages/publications/56949087305

U2 - 10.1016/j.vaccine.2008.09.073

DO - 10.1016/j.vaccine.2008.09.073

M3 - Artículo

C2 - 18930097

AN - SCOPUS:56949087305

SN - 0264-410X

VL - 26

SP - 6844

EP - 6851

JO - Vaccine

JF - Vaccine

IS - 52

ER -

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this